Boron clusters (ferrabisdicarbollides), shaping the future as radiosensitizers for multimodal (chemo/radio/PBFR) therapy of glioblastoma (CROSBI ID 316861)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Nuez, Miquel ; Queralt-Martín, María ; Muñoz-Juan, Amanda ; Aguilella, Vicente M. ; Laromaine, Anna ; Teixidor, Francesc ; Vinas, Clara ; Pinto, Catarina G. ; Pinheiro, Teresa ; Guerreiro, Joana ; Mendes, Filipa ; Rodrigues, Catarina ; Baptista, Pedro V. ; Fernandes, Alexandra R ; Valić, Srećko ; Marques, Fernanda M.
engleski
Boron clusters (ferrabisdicarbollides), shaping the future as radiosensitizers for multimodal (chemo/radio/PBFR) therapy of glioblastoma
Glioblastoma multiforme (GBM) is the most common and fatal primary brain tumor, and is highly resistant to conventional radiotherapy and chemotherapy. Therefore, the development of multidrug resistance and tumor recurrence are frequent. Given the poor survival with the current treatments, new therapeutic strategies are urgently needed. Radiotherapy (RT) is a common cancer treatment modality for GBM. However, there is still a need to improve RT efficiency, while reducing the severe side effects. Radiosensitizers can enhance the killing effect on tumor cells with less side effects on healthy tissues. Herein, we present our pioneering study on the highly stable and amphiphilic metallacarboranes, ferrabis(dicarbollides) ([o-FESAN] and [8, 80-I2-o-FESAN]), as potential radiosensitizers for GBM radiotherapy. We propose radiation methodologies that utilize secondary radiation emissions from iodine and iron, using ferrabis(dicarbollides) as iodine/iron donors, aiming to achieve a greater therapeutic effect than that of a conventional radiotherapy. As a proof-of-concept, we show that using 2D and 3D models of U87 cells, the cellular viability and survival were reduced using this treatment approach. We also tested for the first time the proton boron fusion reaction (PBFR) with ferrabis(dicarbollides), taking advantage of their high boron (11 B) content. The results from the cellular damage response obtained suggest that proton boron fusion radiation therapy, when combined with boron-rich compounds, is a promising modality to fight against resistant tumors. Although these results are encouraging, more developments are needed to further explore ferrabis(dicarbollides) as radiosensitizers towards a positive impact on the therapeutic strategies for GBM.
Boron clusters ; radiosensitizers ; multimodal (chemo/radio/PBFR) therapy ; glioblastom
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
10
2022.
9794-9815
objavljeno
2050-750X
2050-7518
10.1039/d2tb01818g
Povezanost rada
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje), Farmacija, Kemija